ArticleCancer causes & control : CCC2026
Temporal changes in sex and race/ethnicity incidence rate ratios for hepatocellular carcinoma in the United States, 1992-2022.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe incidence of hepatocellular carcinoma (HCC) has increased in the United States. Historically, HCC rates are higher among males than females and among racial and ethnic minorities compared with non-Hispanic White (NHW) individuals. However, HCC incidence patterns have changed over time. We examined how sex and race/ethnicity-specific incidence rate ratios (IRR) for HCC have evolved.
methodsAge-adjusted HCC incidence rates were calculated using the Surveillance Epidemiology and End Results (SEER) 12 Program. Trends in sex- and race/ethnicity-specific IRRs were evaluated overall and by age group (< 50 vs. ≥50 years). IRRs were calculated as the ratio of age-adjusted rates for each comparison group to the reference group (male-to-female; racial/ethnic group-to-NHW), allowing assessment of relative disparities independent of absolute incidence.
resultsFrom 1992 to 2022, 68,023 HCC cases were identified. Incidence increased through the early 2010s before stabilizing and declining after 2015. HCC incidence remained higher among males than females; however, the male-to-female IRR declined from 3.29 to 3.11, with the most pronounced decline among adults aged <50 years. The non-Hispanic Asian/Pacific Islander (NHAPI)-to-NHW IRR declined from 5.86 to 1.87, while non-Hispanic Black (NHB)-to-NHW and Hispanic-to-NHW IRRs declined more modestly. Age-stratified analyses showed more pronounced declines in some relative disparities among younger adults, although several estimates were not statistically significant.
conclusionsSex- and race/ethnicity-specific relative disparities in HCC incidence narrowed over three decades. These findings indicate attenuation of relative disparities, while substantial differences in absolute HCC incidence persisted across demographic groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.